Related Experiment Video

Updated: Jun 21, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Anti-angiogenic therapy in renal cell carcinoma

Shree G Sharma1, Sudip Nanda, Santo Longo

  • 1Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. drshreegopal@gmail.com

Recent Patents on Anti-Cancer Drug Discovery
|July 16, 2009
PubMed

Insights

Renal cell carcinoma (RCC) treatment is advancing due to translational research. Targeting vascular endothelial growth factor (VEGF) with antiangiogenic therapy shows promise for this common cancer.

Area of Science:

  • Oncology
  • Translational Research
  • Molecular Biology

Background:

  • Renal cell carcinoma (RCC) is a prevalent cancer in the United States.
  • RCC is characterized as a highly vascular neoplasm.
  • Recent translational research has significantly improved RCC treatment strategies.

Purpose of the Study:

  • To highlight advancements in renal cell carcinoma treatment.
  • To emphasize the role of antiangiogenic therapy in RCC management.
  • To identify key molecular targets in RCC pathogenesis.

Main Methods:

  • Review of recent translational research findings.
  • Analysis of the biological basis of RCC vascularity.
  • Identification of molecular pathways implicated in RCC development.

Main Results:

  • Antiangiogenic therapy has emerged as a key treatment strategy for RCC.
  • Vascular endothelial growth factor (VEGF) is a critical molecular target.
  • Patents have been filed for anti-VEGF therapies and other related pathways.

Conclusions:

  • Understanding RCC biology, particularly its vascular nature, is crucial for effective treatment.
  • VEGF-targeted therapies represent a significant development in managing renal cell carcinoma.
  • Further research into molecular pathways holds potential for novel RCC treatments.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Imaging Studies VII: Vascular Imaging01:19

Imaging Studies VII: Vascular Imaging

DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...